Antimigraine Agent, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
CSA NA – FDA Approved – REMS (N) – Can Ship
How Does It Work
Erenumab, Aimovig is a human monoclonal antibody that antagonizes calcitonin gene-related peptide (CGRP) receptor function and essentially prevents CGRP from emitting migraine-associated pain signals.
Indications For Use
Before starting Erenumab, Aimovig makes sure your physician is aware of any allergies or medications you currently take. Erenumab, Aimovig can cause constipation after the first dose; however, later onset constipation has also been reported. A new-onset and worsening of pre-existing hypertension can occur when using Erenumab, Aimovig and blood pressure should subsequently be monitored while on treatment.
Subcutaneous: Inject 70mg once monthly; some patients have benefited from a higher dose of 140mg once monthly.
Missed dose: Administer missed dose as soon as possible, and schedule next dose for 1 month from the date of the last dose.
Pharmacist Tips On Using
How to Take:
Inject subcutaneously out of the direct sunlight and allow to come to room temperature for 30 minutes before administration. Do not warm using a heat source (i.e. hot water, microwave) and do not shake. Administer in the abdomen (avoiding 2 inches around the navel), thigh or upper arm, avoiding areas of skin that are tender, bruised, red or hard. Deliver entire contents of single-use autoinjector or prefilled syringe.
Constipation, antibody development, injection site reaction, muscle cramps and spasm.
Note this is not a complete list of side effects for Erenumab, Aimovig only common ones.
Frequently Asked Questions
What do I do if side effects are intolerable?
If side effects are causing a lot of distress speak to your physician as soon as possible to discuss options.